Lack of Diversification. The Company is formed solely for the purpose of developing, producing and exploiting the Picture. Therefore, the financial performance of the Company is solely dependent upon the success of its Picture. In addition, the financial performance of the investment in Company is dependent upon the ability of Company to complete the Picture in a timely and cost-effective manner, the ability of Company to obtain successful theatrical distribution of the Picture and the ultimate audience appeal of the Picture if and when completed.
Lack of Diversification. The Partnership's fundamental purpose will be to operate the Lithotripsy Systems. Because the Partnership is dependent on only one line of business, it will have greater risks from unexpected service interruptions, equipment breakdowns, technological developments, kidney stone treatment medical breakthroughs, economic problems and similar matters than would be the case with a more diversified business.
Lack of Diversification. The Company’s proposed operations, even if successful, will in all likelihood result in the Company’s engaging in a business which is concentrated in only one industry. Consequently, the Company’s activities will be limited to the anti-counterfeiting industry. The Company’s inability to diversify its activities into a number of areas may subject the Company to economic fluctuations within a particular business or industry and, therefore, increase the risks associated with the Company’s operations.
Lack of Diversification. The Company's proposed business involving the proposed operation of establishments offering "female exotic entertainment" will not provide any diversification. If the Company is successful, all of the Company's business and assets will be concentrated in the same industry.
Lack of Diversification. The development and operation of the Company is limited to a narrowly-focused business serving a single industry segment in a localized geographic area. Due to this lack of diversification, the Company may be subject to greater risk of loss from local, industry-specific or participant-specific risks than would be the case with a more diversified enterprise.
Lack of Diversification. All of the Company's assets will be committed to the development and operation of the Business. As a result, the Company will lack diversification in its assets and the potential profitability of the Company (and therefore the Shares) will be limited solely to the profitability of the Business, which could be adversely affected by many factors, including, among other things, a downturn it the luxury activewear industry.
Lack of Diversification. The Company’s business is manufacture of paper. In view of the limited scope of its limited business, it may have greater risks from casualties, competition, economic problems and similar matters than would be the case with a more diversified company.
Lack of Diversification. The Partnership's principal purpose will be to continue to operate the Mobile Lithotripsy System. Because the Part-ner-ship is dependent on only one line of business and one Mobile Lithotripsy System, there will be greater risks from unexpected service interruptions, equipment breakdowns, technological developments, kidney stone treatment medical breakthroughs, economic problems and similar matters than would be the case with a more diversified business.
Lack of Diversification. At the present time, Buyer intends to invest only in dely-style restaurants and related food operations. As a result, changes in consumer preferences, including a change in consumer preferences for restaurants of the type operated by Buyer, may have a disproportionate and materially adverse impact on Buyer's business and its operating results.
Lack of Diversification. The Partnership's principal purpose will be to continue to operate the Lithotripsy System. Because the Partnership is dependent on only one line of business and one Lithotripsy System, there will be greater risks from unexpected service interruptions, equipment breakdowns, technological developments, kidney stone treatment medical breakthroughs, economic problems and similar matters than would be the case with a more diversified business. W##889140 V2 - MOBILE KIDNEY-CONF PPM.DOC Impact of Insurance Reimbursement. The Partnership's revenues are expected to be derived from the fees paid by Contract Hospitals and other health care facilities under lithotripsy service contracts with the Partnership. The Partnership does not currently directly bill or collect for services from patients or their third-party payors. Payments received from Contract Hospitals and other health care facilities may be subject to renegotiation depending on the reimbursement such parties receive. The increasing influence of health maintenance organizations and other managed care companies has resulted in pressure to reduce the reimbursement available for lithotripsy procedures. Some of the General Partner's Affiliates have recently experienced declining revenues based on these managed care pressures in other health care markets. Additionally, the Health Care Financing Administration ("HCFA"), the federal agency which administers the Medicare program, has proposed rules which would reduce the reimbursement available for lithotripsy procedures provided at hospitals to $2,235. See "Regulation - Federal Regulation." In some cases reimbursement rates payable to the General Partner and other Affiliates are less than the proposed HCFA rate. Because of the competitive pressures from managed care companies as well as threatened reductions in Medicare reimbursement, the General Partner anticipates that reimbursement available for lithotripsy procedures may continue to decrease. Such decreases would have a material adverse effect on Partnership revenues. Regarding the professional fees paid to physicians who treat patients on the Lithotripsy System, the General Partner anticipates that similar competitive pressures may result in lower reimbursement paid to physicians, both by private insurers and by government programs such as Medicare. See "Regulation." Reliability and Efficacy of the Storz Modulith(R) SLX-T. The Modulith(R) SLX-T received FDA premarket approval on March 27, 1997. Although, the ...
